#276 ‒ Special episode: Peter answers questions on longevity, supplements, protein, fasting, apoB, statins, and more
“One of the most important things to understand when you are using some sort of intervention is, do you have a biomarker to know if you’re doing it correctly?” —Peter Attia
#272 ‒ Rapamycin: potential longevity benefits, surge in popularity, unanswered questions, and more | David Sabatini, M.D., Ph.D. and Matt Kaeberlein, Ph.D.
“[Rapamycin] is the most robust and reproducible drug that we know about today for impacting not only longevity, but to the extent that we can measure various metrics of healthspan in complex animals, rapamycin also seems to positively impact pretty much every aspect of health span that we measure.” —Matt Kaeberlein
#270 ‒ Journal club with Andrew Huberman: metformin as a geroprotective drug, the power of belief, and how to read scientific papers
“This paper basically addresses how our beliefs about the drugs we take impacts how they affect us at a real level, not just at a subjective level, but at a biological level.” —Andrew Huberman
#222 ‒ How nutrition impacts longevity | Matt Kaeberlein, Ph.D.
“It’s really important that we be willing to change our beliefs about nutrition and other aspects of health as more data comes in.” —Matt Kaeberlein
The difference between a ‘clean’ drug and a ‘dirty’ drug
This clip is from episode #207 – AMA #35: “Anti-Aging” Drugs — NAD+, metformin, & rapamycin, originally released on May…
#207 – AMA #35: “Anti-Aging” Drugs — NAD+, metformin, & rapamycin
“It’s really hard to know, in my view, how important sirtuins are as longevity factors…If we accept that, then it’s difficult to know [the importance of] activation of sirtuins by NAD as a longevity mechanism.” —Matt Kaeberlein
#204 – Centenarians, metformin, and longevity | Nir Barzilai, M.D.
“If you prevent aging and age-related disease, you’re going to compress morbidity, too.” — Nir Barzilai
#175 – Matt Kaeberlein, Ph.D.: The biology of aging, rapamycin, and other interventions that target the aging process
“I don’t think I will ever understand aging fully. And I don’t think the field will. … But I also believe that we don’t have to understand it fully to be able to have an impact on the biology of aging through interventions.” —Matt Kaeberlein
Rapamycin risks?
The importance of good science and good interpretation
#171 – Steve Austad, Ph.D.: The landscape of longevity science: making sense of caloric restriction, biomarkers of aging, and possible geroprotective molecules
“I never thought [extending the human lifespan] was going to happen because we got better at treating cancer or we got better at preventing heart disease. I always thought it was going to happen because we would develop something … that would fundamentally change the rate of aging. And we haven’t developed that yet. We’ve got a lot of clues and I think we’re getting closer and closer and closer.” —Steve Austad